SkinBioTherapeutics (LSE:SBTX) Research & Development: £0.17 Mil (TTM As of Dec. 2025)


LSE:SBTX SkinBioTherapeutics PLC LSE:SBTX
40 GF Score
Price £0.12
GF Value £0.64
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SkinBioTherapeutics Research & Development?

SkinBioTherapeutics LSE:SBTX +8.89% 40 Research & Development is £0.17 Mil as of Dec. 2025. GuruFocus rates LSE:SBTX with a GF Score™ of 40/100 and a GF Value™ of £0.64 (Possible Value Trap). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. SkinBioTherapeutics's Research & Development for the six months ended in Dec. 2025 was £0.06 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was £0.17 Mil.

SkinBioTherapeutics  (LSE:SBTX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

SkinBioTherapeutics Research & Development Related Terms

SkinBioTherapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for SkinBioTherapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SkinBioTherapeutics Research & Development Chart

SkinBioTherapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.86 0.93 0.56 0.13

SkinBioTherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.32 0.01 0.12 0.06
LSE:SBTX
40GF Score
SkinBioTherapeutics PLC LSE:SBTX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SkinBioTherapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.17 Mil mean?
SkinBioTherapeutics (LSE:SBTX) has a Research & Development of £0.17 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on SkinBioTherapeutics and its competitors.
Is SkinBioTherapeutics' Research & Development too high?
SkinBioTherapeutics' current Research & Development is £0.17 Mil. Overall, SkinBioTherapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SkinBioTherapeutics' Research & Development compare to VRTX and REGN?
SkinBioTherapeutics' Research & Development of £0.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on SkinBioTherapeutics and its competitors. SkinBioTherapeutics's current Research & Development is £0.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SkinBioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, SkinBioTherapeutics (LSE:SBTX) is currently considered Possible Value Trap. The stock's GF Value™ is £0.64, compared to a current price of £0.12 — trading 80.9% below its estimated fair value. The current Research & Development is £0.17 Mil. SkinBioTherapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For SkinBioTherapeutics (LSE:SBTX), the current Research & Development is £0.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SkinBioTherapeutics (LSE:SBTX) Overvalued in 2026?

Based on GuruFocus' analysis, SkinBioTherapeutics stock appears to be undervalued. The current stock price of £0.12 is trading 80.9% below its estimated GF Value™ of £0.64. GuruFocus considers SkinBioTherapeutics to be Possible Value Trap.

Key valuation signals for LSE:SBTX:

  • Research & Development: £0.17 Mil
  • GF Value™: £0.64 vs. price of £0.12 (80.9% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the LSE:SBTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SkinBioTherapeutics Business Description

Address Bath Lane, The Core, Newcastle Helix, Newcastle upon Tyne, GBR, NE4 5TF
SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.
40GF Score

Get the complete analysis for LSE:SBTX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.12
Price
£0.64
GF Value